1990-2015年荷兰儿童和青少年急性淋巴细胞白血病的防治进展
该研究基于荷兰癌症登记处和荷兰儿童肿瘤学组数据,评估1990-2015年26年间<18岁急性淋巴细胞白血病(ALL)的流行病学进展。共诊断2997例ALL患者,年发病115例(范围87-147),总发病率稳定在37/百万儿童;5年生存率从1990-94年的80%升至2010-15年的91%(p<0.01),死亡率年降4%(p<0.01);15-17岁患者在儿童肿瘤中心治疗比例从35%升至87%,其死亡风险较非儿童肿瘤中心治疗者降低70%(p<0.01)。
要点
- 1990-2015年荷兰<18岁ALL总发病率稳定在37/百万儿童。
- 5年生存率从1990-94年80%升至2010-15年91%(p<0.01)。
- 15-17岁患者在儿童肿瘤中心治疗比例从35%升至87%,死亡风险降低70%(p<0.01)。
核心结论
- 荷兰儿童ALL防治取得显著进展,生存率提高与死亡率下降相一致,总发病率稳定,但10-14岁B细胞前体ALL和15-17岁T细胞ALL发病率有所上升。
研究设计与样本
- 从荷兰癌症登记处和荷兰儿童肿瘤学组选取<18岁ALL患者,进行随时间、年龄组和ALL亚型分层的趋势分析,1990-2015年共诊断2997例,年发病115例(范围87-147)。
主要发现
- 总发病率稳定在37/百万儿童;10-14岁B细胞前体ALL年均百分比变化(AAPC)+1.4%(p=0.04),15-17岁T细胞ALL的AAPC+3.7%(p=0.01)。
- 5年生存率从1990-94年80%升至2010-15年91%(p<0.01),死亡率每年下降4%(p<0.01)。
- 15-17岁患者在儿童肿瘤中心治疗比例从1990-94年35%升至2010-15年87%,其死亡风险较非儿童肿瘤中心治疗者降低70%(p<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age group and ALL subtype. Between 1990 and 2015, 2997 ALL patients were diagnosed, i.e. 115 patients (range 87-147) per year. Overall incidence remained stable at 37 per million children, despite increases for B-cell precursor ALL (BCP-ALL) at age 10-14 years (AAPC + 1.4%, p = 0.04) and T-cell ALL at 15-17 years (AAPC + 3.7%, p = 0.01). Five-year survival increased from 80% in 1990-94 to 91% in 2010-15 (p < 0.01). Mortality decreased by 4% annually (p < 0.01). Patients 15-17 years were increasingly treated in a paediatric oncology centre, from 35% in 1990-94 to 87% in 2010-15 and experienced a 70% reduction of risk of death compared to those treated outside such a centre (p < 0.01). Significant progress against childhood ALL has been made in the Netherlands, visible by improved survival rates coinciding with declining mortality rates. These outcomes were accompanied by stable incidence rates, despite increases for BCP-ALL at age 10-14 years and T-cell ALL at age 15-17 years.
引用
- Reedijk AMJ, Coebergh JWW, de Groot-Kruseman HA, et al. Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015. Leukemia. 2020. PMID: 32820270. doi:10.1038/s41375-020-01024-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。